Fecal microbiota transplant for Crohn disease: A study evaluating safety, efficacy, and microbiome profile

Single-dose FMT in this cohort of CD patients showed modest effect and potential for harm. Responders tended to have lower baseline alpha diversity, suggesting baseline perturbation of microbiota may be an indicator of potential responders to FMT in this patient population. Controlled trials are needed to further assess the efficacy and safety of FMT in CD and determine whether FMT is a viable option in this patient population.<b>Clinicaltrials.gov number:</b> NCT02460705.